Pharmacy Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

New Data Shows AZOR (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Daiichi Sankyo, 05/11/09

Daiichi Sankyo, Inc. announced that data presented at the American Society of Hypertension, Inc. Twenty-Fourth Annual Scientific Meeting and Exposition in San Francisco from the AZOR Trial Evaluating Blood Pressure Reductions and Control demonstrated that a stepwise amlodipine and olmesartan medoxomil-based titration regimen provided mean 24-hour ambulatory reductions in systolic blood pressure of 21.4 mm Hg and diastolic blood pressure of 12.7 mm Hg. In addition, 71 percent of patients in the study were able to safely and effectively achieve a 24-hour ambulatory target blood pressure of <130/80 mm Hg. The study also showed large mean 24-hour ambulatory BP reductions in patients with hypertension from two groups with elevated risk for developing hypertension, Blacks and patients with type 2 diabetes.

<< Previous
Ongoing Landmark ROADMAP Study Demonstrates Significant...

Next >>
EEG abnormalities during treatment with tadalafil, a...